V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
https://european-biotechnology.com/wp-content/uploads/2024/04/V-BIO.jpg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-07 17:35:452021-02-07 17:35:45V-Bio Ventures launches second fund at €78m
https://european-biotechnology.com/wp-content/uploads/2024/04/VC_money.jpg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-03 12:44:122021-02-03 12:44:12Abingworth raises US-$465m for new life sciences fund
https://european-biotechnology.com/wp-content/uploads/2024/04/Rentschler-Biopharma-headquarters.jpg7991200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-02 06:00:572021-02-02 06:00:57Rentschler Biopharma to produce 100m doses of CureVac vaccine
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
https://european-biotechnology.com/wp-content/uploads/2024/04/GeldLSP.jpg9721280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-28 16:47:432021-01-28 16:47:43Italian Enthera Pharma raise €35m in Series A extension
https://european-biotechnology.com/wp-content/uploads/2024/04/novel-coronavirus-sars-cov-2_49666286236_o.jpg17862100Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-27 08:57:152021-01-27 08:57:15German antibodies in demand in USA
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-01-27 08:30:002021-01-27 08:30:00Accure Therapeutics named new CMO
https://european-biotechnology.com/wp-content/uploads/2024/04/Omnix_Medical.jpg320640Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-25 11:46:402021-01-25 11:46:40Omnix Medical bags €10.8m from EIC Accerator Fund
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2021-01-25_um_10.38.27.png553949Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-25 10:23:502021-01-25 10:23:50Germany orders antibody therapies from USA
French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
V-Bio Ventures launches second fund at €78m
Latest NewsV-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
Latest NewsThe transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
Latest NewsAs rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
Latest NewsGerman CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise €35m in Series A extension
Latest NewsEnthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
German antibodies in demand in USA
Latest NewsA US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Accure Therapeutics named new CMO
AppointmentsSpanish Accure Therapeutics appoints Dr Rossella Medori as new Chief Medical officer.
Omnix Medical bags €10.8m from EIC Accerator Fund
Latest NewsGermany orders antibody therapies from USA
Latest NewsGermany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign €220m deal
Latest NewsFrench Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.